CGTLive’s Weekly Rewind – April 21, 2023

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Here to Stay: Progress Solidifies the Future of Cell Therapy

CGTLive takes a look at recent progress in cell therapy development targeting solid tumors, featuring expert commentary on these advances.

2. Matthew D. Weitzman, PhD, and Matthew Charman, PhD, on Studying the DNA Virus Replication Process

The investigators from Children’s Hospital of Philadelphia discussed the potential implications of their research into human adenoviruses for the development of new gene delivery tools.

3. CARTITUDE-4 Data Leak Reveals Promising Results for Cilta-Cel in Multiple Myeloma

The CAR-T therapy reduced disease progression risk by 74%, according to a data leak reported by STAT News. The data are expected to be presented on May 11 at the 2023 European Hematology Association Congress.

4. Samer Srour, MB ChB, MS, on Proof-of-Concept of Allogeneic CAR T in Renal Cell Carcinoma

The assistant professor of stem cell transplantation at MD Anderson Cancer Center discussed updated data on ALLO-316 in patients with ccRCC.

5. FDA Approves Omidubicel to Reduce Infection Risk in Patients With Hematologic Malignancies Undergoing Stem Cell Transplant

Infection rates in patients receiving omidubicel post-stem cell transplant were about 20% less than those in the control group.